Literature DB >> 23407399

Screening for anxiety symptoms in Parkinson disease: a cross-sectional study.

Elka Stefanova1, Ljubomir Ziropadja, Mirjana Petrović, Tanja Stojković, Vladimir Kostić.   

Abstract

BACKGROUND: A limited number of studies examined anxiety in Parkinson disease (PD). Questionable validity of the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) defined anxiety disorders in PD population as well as a lack of validated rating scales hampered the investigation in this field.
OBJECTIVE: To screen for prevalence of anxiety symptoms and their associated demographic and clinical features in an outpatient-based cohort with PD. PATIENTS AND METHODS: A consecutive series of 360 patients with PD underwent investigation with the Hamilton Anxiety Rating Scale (HARS), the 17-item Hamilton Depression Rating Scale, Neuropsychiatric Inventory, section E (anxiety), motor scoring with Hoehn and Yahr staging, the Unified Parkinson's Disease Rating Scale, and cognitive screening with the Mini-Mental State Examination.
RESULTS: In all, 136 (37.8%) patients with PD of our cohort had anxiety symptoms, whereas both depression and anxiety were recorded in 5.6% of the patients, while in 56.7% neither anxiety nor depression was present. Female gender, motor disability, and core depression symptoms were the main markers of anxiety in patients with PD. The severity of anxiety symptoms was not associated with asymmetry of motor symptoms. Education, disease duration, and levodopa dose were poor predictors in the model. The HARS had a satisfactory inter-item correlation, convergent validity, and factorial structure.
CONCLUSIONS: Anxiety may be present as an isolated symptom, with specific demographic and clinical markers, and not only as a feature of depression in PD population. This highlighted the importance of identifying anxiety symptoms when treating patients with PD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23407399     DOI: 10.1177/0891988713476368

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  10 in total

1.  Neuropsychiatric characteristics of GBA-associated Parkinson disease.

Authors:  Matthew Swan; Nancy Doan; Robert A Ortega; Matthew Barrett; William Nichols; Laurie Ozelius; Jeannie Soto-Valencia; Sarah Boschung; Andres Deik; Harini Sarva; Jose Cabassa; Brooke Johannes; Deborah Raymond; Karen Marder; Nir Giladi; Joan Miravite; William Severt; Rivka Sachdev; Vicki Shanker; Susan Bressman; Rachel Saunders-Pullman
Journal:  J Neurol Sci       Date:  2016-08-30       Impact factor: 3.181

2.  Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias.

Authors:  Jared T Hinkle; Kate Perepezko; Liana S Rosenthal; Kelly A Mills; Alexander Pantelyat; Zoltan Mari; Laura Tochen; Jee Yun Bang; Medha Gudavalli; Nadine Yoritomo; Ankur Butala; Catherine C Bakker; Vanessa Johnson; Emile Moukheiber; Ted M Dawson; Gregory M Pontone
Journal:  Parkinsonism Relat Disord       Date:  2017-11-21       Impact factor: 4.891

3.  Characteristics and Treatment of Anxiety Disorders in Parkinson's Disease.

Authors:  Nadeeka N W Dissanayaka; Elizabeth White; John D O'Sullivan; Rodney Marsh; Peter A Silburn; David A Copland; George D Mellick; Gerard J Byrne
Journal:  Mov Disord Clin Pract       Date:  2015-04-06

Review 4.  Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease.

Authors:  Edward C Lauterbach
Journal:  Am J Neurodegener Dis       Date:  2016-03-01

5.  BST1 rs4698412 allelic variant increases the risk of gait or balance deficits in patients with Parkinson's disease.

Authors:  Yu-Ting Shen; Jian-Wei Wang; Min Wang; Yan Zhi; Jun-Yi Li; Yong-Sheng Yuan; Xi-Xi Wang; Hui Zhang; Ke-Zhong Zhang
Journal:  CNS Neurosci Ther       Date:  2019-01-24       Impact factor: 5.243

6.  Identifying Depression in Parkinson's Disease by Using Combined Diffusion Tensor Imaging and Support Vector Machine.

Authors:  Yunjun Yang; Yuelong Yang; Aizhen Pan; Zhifeng Xu; Lijuan Wang; Yuhu Zhang; Kun Nie; Biao Huang
Journal:  Front Neurol       Date:  2022-06-20       Impact factor: 4.086

7.  Evaluating the Link Between Dopaminergic Treatment, Gait Impairment, and Anxiety in Parkinson's Disease.

Authors:  Kaylena A Ehgoetz Martens; Colin G Ellard; Quincy J Almeida
Journal:  Mov Disord Clin Pract       Date:  2016-01-09

8.  Relationships among Depression, Anxiety, Sleep, and Quality of Life in Patients with Parkinson's Disease in Taiwan.

Authors:  Jun-Yu Fan; Bao-Luen Chang; Yih-Ru Wu
Journal:  Parkinsons Dis       Date:  2016-05-15

Review 9.  Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review.

Authors:  Marie Grall-Bronnec; Anne Sauvaget; Fanny Perrouin; Juliette Leboucher; François Etcheverrigaray; Gaëlle Challet-Bouju; Louise Gaboriau; Pascal Derkinderen; Pascale Jolliet; Caroline Victorri-Vigneau
Journal:  J Clin Psychopharmacol       Date:  2016-02       Impact factor: 3.153

10.  Altered putamen functional connectivity is associated with anxiety disorder in Parkinson's disease.

Authors:  Xixi Wang; Junyi Li; Yongsheng Yuan; Min Wang; Jian Ding; Jiejin Zhang; Lin Zhu; Yuting Shen; Hui Zhang; Kezhong Zhang
Journal:  Oncotarget       Date:  2017-07-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.